A double-blind controlled trial of two dose levels of factor VIII in the treatment of high risk haemarthroses in haemophilia A.
One hundred and thirteen haemarthroses involving the knees, ankles and elbows of 29 severe haemophiliacs presenting with at least two of the risk factors, pain, tenderness, loss of more than 50% of movement and a delay of more than 3 h in treatment were studied. Each was given either a 20% or 40% dose of factor VIII and progress was then reviewed by medical staff unaware of the initial dosage. There was no significant effect on the retransfusion rate nor on the time to complete resolution. However, the difference between the percentage of patients showing residual movement restriction was significantly in favour of the high dose at 24, 36 and 48 h when all the bleeds were pooled and at 48 h for elbow bleeds.
D001803:Blood Transfusion; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004551:Elbow Joint; D005169:Factor VIII / Q000008:administration & dosage*; D006395:Hemarthrosis / Q000209:etiology / Q000628:therapy*; D006467:Hemophilia A / Q000150:complications*; D006801:Humans; D007719:Knee Joint; D008297:Male; D013997:Time Factors
D005169:Factor VIII